PDL BioPharma Inc. (NASDAQ: PDLI) dropped 5% on Monday to post a new 52-week low of $6.52 against a 52-week high of $10.26. The stock closed at $6.87 on Friday night. Volume was about equal to the daily average of around 4 million shares. The company had no specific news today, but is scheduled to report first quarter results on Wednesday.
3D Systems Corp. (NYSE: DDD) dropped 1.6% on Monday to add to post a new 52-week low of $24.51 after closing at $24.92 on Friday. The stock’s 52-week high is $69.56. Share volume was about 30% below the daily average of around 2.8 million shares traded. The company announced a distribution deal this morning, but the stock price fades as investors await first quarter results, also due Wednesday from the 3D printer maker.
Zulily Inc. (NASDAQ: ZU) also posted a second consecutive 52-week low on Monday. Shares dropped 2.2% to $11.88 from Friday’s closing price of $12.15. The stock’s 52-week high is $50.39. Volume was about 10% above the daily average of around 2.6 million shares. The company had no news today.
Keryx Biopharmaceuticals Inc. (NASDAQ: KERX) dropped about 10% on Monday to post a new 52-week low of $9.80 after closing at $10.90 on Friday. The stock’s 52-week high is $18.48. Share volume was more than double the daily average of around 1.6 million shares traded. The company reported a first quarter loss this morning.
ALSO READ: 15 Companies Losing the Most Money
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
